Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $730.36 MXN
Change Today +1.08 / 0.15%
Volume 1.7K
SNYN On Other Exchanges
EN Paris
As of 4:09 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - $895.65
52 Week Low
01/7/15 - $659.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi-adr (SNYN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi-adr (SNYN) Key Developments

Sanofi and Regeneron Pharmaceuticals, Inc. Complete Enrollment in the Global Phase 3 ODYSSEY OUTCOMES Trial

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular (CV) benefits of Praluent(R) (alirocumab) Injection after an acute coronary syndrome (ACS). The 18,000-patient ODYSSEY OUTCOMES trial is expected to be completed in 2017. ODYSSEY OUTCOMES is designed to determine whether the addition of Praluent to intensive statin therapy reduces major adverse cardiac events among patients who had previously experienced an ACS, such as a heart attack or unstable angina. The primary endpoint evaluates the time to first occurrence of coronary heart disease death, acute myocardial infarction, hospitalization for unstable angina, or fatal and non-fatal ischemic stroke. Patients with recent ACS were selected as the study population because they face a higher risk of recurrent events than patients with stable cardiovascular disease. Praluent is currently approved in the U.S. and EU to reduce bad (LDL) cholesterol in some patients with significant unmet need, including those with established cardiovascular disease, or an inherited form of high cholesterol, called heterozygous familial hypercholesterolemia (HeFH). The effect of Praluent on CV morbidity and mortality has not been determined. The global ODYSSEY program includes 16 Phase 3 trials conducted at more than 2,000 study centers, around the world, and once complete will evaluate more than 25,000 patients. Data from this program helped form one of the most comprehensive data sets ever used for the initial regulatory filing of a cholesterol-lowering therapy. In completed trials, Praluent reduced LDL cholesterol by up to an additional 62% versus placebo, and was generally well-tolerated with an acceptable safety profile. Do not use PRALUENT if allergic to alirocumab or to any of the ingredients in PRALUENT. Before start using PRALUENT, tell healthcare provider about all medical conditions, including allergies, and if pregnant or plan to become pregnant or if breastfeeding or plan to breastfeed. PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms.

Sanofi and AstraZeneca Announces Major Drug-Sharing Deal

Sanofi and AstraZeneca announced that they have agreed to share freely 210,000 proprietary chemical compounds as they pursue the development of new drugs. Sanofi hailed the move as a new open innovation model between two major pharmaceutical groups who normally are major competitors in a multibillion business creating the building blocks of treatments for diseases. The novel arrangement of exchanging compounds from their separate compound libraries will allow both to sift a much larger and more diversified number of small molecules likely to become future medicines. The contents of the libraries are usually kept closely under wraps. AstraZeneca hailed the multi-year accord, which will reduce the need to spend tens of millions of dollars in developing the compounds separately. Those which look promising will be classified as lead compounds to be taken forward for development.

Sanofi Partners with Lexicon Pharmaceuticals to Develop Diabetes Solution

Sanofi is partnering with Lexicon Pharmaceuticals to develop and commercialize sotagliflozin to treat diabetes. The deal was struck a day after Sanofi announced a licensing deal worth $4.2 billion with Hanmi Pharmaceutical for rights to a trio of next-generation diabetes medicine. Sotagliflozin is being studied in two pivotal Phase 3 trials in Type 1 diabetes, and Phase 3 trials in Type 2 diabetes are expected to begin in 2016. Lexicon will receive an upfront payment of $300 million, with the potential of milestone payments up to $1.4 billion. The company will be responsible for clinical development, and Sanofi will gain exclusive worldwide rights to develop, manufacture and commercialize sotagliflozin.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $730.36 MXN +1.08

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $163.95 USD +1.17
Bayer AG €126.65 EUR +1.85
Bristol-Myers Squibb Co $68.08 USD +0.26
Medtronic PLC $76.56 USD 0.00
Novo Nordisk A/S kr386.10 DKK +3.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SNYN Industry Range
Price/Earnings 19.9x
Price/Sales 2.8x
Price/Book 1.8x
Price/Cash Flow 13.4x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SANOFI-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at